Skip to main content
. 2022 Mar 2;6(5):1444–1453. doi: 10.1182/bloodadvances.2021005035

Figure 2.

Figure 2.

Ruxolitinib pharmacokinetics. Days −2 to +4 (A) and +5 (B). AUC, area under the plasma concentration–time curve; BID, twice daily; CL/F, oral clearance; Cmax, maximum plasma concentration; PK, pharmacokinetics; T1/2, terminal-phase elimination half-life.